PITTSBURGH--(BUSINESS WIRE)--Precision Therapeutics will proudly continue its dedicated support to the NOCC Pittsburgh Chapter's 13th Annual Walk to Break the Silence on Ovarian Cancer. Precision has been a strong supporter of the NOCC 5 Mile Run/5 Mile & 1 Mile walk for over five years, and once again expects a great number of its employees will join together in full force to walk alongside ovarian cancer patients and survivors to help strengthen the partnerships it has forged by supporting the very cancer patients that it strives to help.
As part of its sponsorship, Precision will reward every employee participating in the race with a pre-paid registration.
“As we build on our success in personalized cancer treatment and look to the entire continuum of cancer care, the NOCC Walk to Break the Silence is one of the most prestigious fundraisers with which we could be affiliated,” said Sean McDonald, President and CEO of Precision Therapeutics. “We’re honored to be part of this event, which supports the promotion of ovarian cancer awareness.”
The NOCC Walk to Break the Silence will take place on Sunday, September 8, 2013 at the North Park Boathouse in Pittsburgh. For more information on the National Ovarian Cancer Coalition, please visit www.ovarian.org.
ChemoFx® is a proprietary, CLIA-certified and commercially-available chemoresponse assay which measures an individual’s tumor response to a range of therapeutic alternatives under consideration by the treating physician. By testing multiple chemotherapies on a patient's tumor cells before clinically treating a cancer patient, ChemoFx® helps determine the chemotherapies more likely to be effective and provides valuable insights that help inform physicians' treatment decisions with the goal of improving patient outcomes.
Precision Therapeutics currently receives ChemoFx® specimens from 271 top medical institutions including 20 of the 21 National Comprehensive Cancer Network (NCCN) Member Institutions, and 8 of the US News and World Report Top 10 Hospitals for Cancer Care. Over 60,000 patient specimens to date have been tested with ChemoFx®.
About Precision Therapeutics
Precision Therapeutics is dedicated to utilizing precision medicine for personalized cancer care. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum. The company’s leading products for personalized cancer care include the ChemoFx® chemoresponse assay and BioSpeciFx®, a select portfolio of clinically relevant molecular tests that provide information about drug response and patient prognosis. Precision has received approximately 70,000 patient specimens from over 400 top cancer institutions for BioSpeciFx testing to date. Additionally, in 2013 Precision is releasing two new gene signature products, under the GeneFx® brand.